Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryManagement of anemia in patients with diabetic kidney disease: A consensus statementManagement of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic controlPostprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinideUpdate on the treatment of type 2 diabetes mellitusPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis.Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot studyLinagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.An observational, cross-sectional study to assess the prevalence of chronic kidney disease in type 2 diabetes patients in India (START -India).Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications.Anti-Hyperglycemic Agents and New-Onset Acute Myocardial Infarction in Diabetic Patients with End-Stage Renal Disease Undergoing DialysisEfficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis.Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptinSafety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database studyLinagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial.Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013.A review of gliptins in 2011.Repaglinide: a review of its use in type 2 diabetes mellitus.Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.Noninsulin glucose-lowering agents for the treatment of patients on dialysis.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.Haemodialysis-induced hypoglycaemia and glycaemic disarrays.Antidiabetic Therapy in End-Stage Renal Disease.Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.Evaluation and management of diabetic and non-diabetic hypoglycemia in end-stage renal disease.Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.Current therapeutic approaches in the management of hyperglycemia in chronic renal disease.Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.The Management of Diabetes Mellitus in Patients with Chronic Kidney Disease: A Population-Based Study in Southern Italy.Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
P2860
Q22241786-3319417E-E496-4E4D-9F8A-AE417E578761Q26752692-BE6BACAE-F318-4039-AB13-E282B06492D4Q26766259-64EAE09D-05DF-42D0-8F73-5D8BC2667A87Q26865976-778CBE03-0A83-4F42-8651-F8F747946D73Q28073342-6BB18A5C-8C1C-4D45-9124-116D2F710BC4Q30249371-7BEC046F-3A84-493F-8AAA-31291974A60AQ33687578-17137650-FE0A-4A52-868B-18FD2C7BA7ECQ34609759-8AE69144-48C0-43CE-AB07-23BF2EE9720CQ34744189-417E3DAE-C1B4-4C24-AE92-0E05A542D530Q34891146-12A6A044-1A51-4DE6-B8AC-31AC90482D67Q35784771-B1ED694B-E244-46B8-99F3-85738DB8E911Q35950538-1945E661-805D-4269-8824-B4563F339435Q36101262-41E0B9D7-A95C-4456-9641-870718DBCD88Q36574084-31E4D4E9-31D2-4FE9-A382-A23F3B336439Q36686365-E7D23C13-954E-446A-A930-9594F041D197Q36805122-EC6B4C0A-CB72-4BE7-8E47-2A7D6918E522Q36809901-216E4246-6D8B-4671-809C-8142EBA7C2D1Q37133799-DADB103E-E29D-475D-815C-27C9AF6C9C10Q37133956-A5BD52A0-D986-4718-BC73-50E02EC15A6AQ37233958-281BAD70-704D-4235-97EE-0624E7402E82Q37965612-4451A708-E13A-4836-BD5A-04A778C548ADQ37977979-4C27B355-B6C0-4229-8011-A54B4CB524E1Q37982112-C19100DD-B65A-4583-BEF8-E83C7581D224Q38012068-922F262E-6F57-4FB5-8228-3CB2E21A5E73Q38036778-557074D3-E5AE-49A2-8584-E118DE1CEA82Q38058568-D6B67EE2-B99E-435E-8B9E-44E1270CFD3CQ38077451-5EBC75A7-7556-4070-8E90-5B2E48859A08Q38086611-738603D0-D878-4C13-A189-6A7B53423BB8Q38200670-3DD06392-CA5B-4120-9040-BC822974FFF6Q38261573-7F711141-6647-4F64-89AE-83BC15A97445Q38409082-3DBD0D16-7090-4596-BA8A-0F01E1C97A55Q38433245-4B34161B-69C9-4DAC-A630-3465126AD58AQ38541323-CCECF170-95F1-41D1-97D3-65DC723B4C7AQ38543658-79D8EFA5-5CD0-4C42-AAC3-C950E97F286FQ38603506-7C393EAA-0F29-48E5-81C8-1E0A8811B784Q39160771-18B98371-4616-4EA2-980A-92681F49CFEFQ40873693-CBD1B3F5-B863-46F0-9F72-B1962F8851A5Q41030612-4AB3D4E0-F93B-4B47-B89E-B7E5D6E4F7C3Q41856389-D10CF95D-02A9-4929-A20B-F17F3F5D893EQ45877987-BAAE5F26-390B-4B5B-B75C-057A3E452790
P2860
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antidiabetic agents in patient ...... abolism and clinical practice.
@en
Antidiabetic agents in patient ...... abolism and clinical practice.
@nl
type
label
Antidiabetic agents in patient ...... abolism and clinical practice.
@en
Antidiabetic agents in patient ...... abolism and clinical practice.
@nl
prefLabel
Antidiabetic agents in patient ...... abolism and clinical practice.
@en
Antidiabetic agents in patient ...... abolism and clinical practice.
@nl
P2093
P1476
Antidiabetic agents in patient ...... abolism and clinical practice.
@en
P2093
Kazuyoshi Okada
Masanori Abe
Masayoshi Soma
P356
10.2174/138920011794520053
P407
P577
2011-01-01T00:00:00Z